Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03393611 · ClinicalTrials.gov registry record · Phase 1
CPX-351 Salvage Therapy Followed by Haplo-Cord Transplant for Relapsed/Refractory Leukemia or Myelodysplastic Syndrome
A Phase 1 study of Myelodysplastic Syndromes and Leukemia, Myeloid, Acute, sponsored by Weill Medical College of Cornell University.
- Completed
- Registry status
- Phase 1
- Development phase
- 14
- Enrollment target
- 1
- Study location
NCT03393611 is a Phase 1 study of Myelodysplastic Syndromes and Leukemia, Myeloid, Acute that has completed, run by Weill Medical College of Cornell University. The registered enrollment target is 14 participants, below the 285-participant average among 173 other Myelodysplastic Syndromes trials with a reported enrollment target (95% lower). The trial reports 1 study location across 1 state.
The verdict
NCT03393611, a Phase 1 study of Myelodysplastic Syndromes and Leukemia, Myeloid, Acute, has completed, sponsored by Weill Medical College of Cornell University.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 14 participants
- Enrollment target
- 1
- Study location
Study Summary
This pilot study is designed to evaluate outcomes with the combination of CPX-351 salvage therapy and haplo-cord graft stem cell transplantation for subjects with relapsed or refractory AML or myelodysplastic syndrome.
Conditions Studied
Interventions
- DRUG Fludarabine
- DRUG Melphalan
- DRUG CPX-351
- DRUG Rabbit Anti-Human T-Lymphocyte Globulin
- BIOLOGICAL Haplo-Cord Stem Cell Transplantation
Study Locations (1)
New York
- Weill Cornell Medical College - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2012-11-30 |
| Est. Completion | 2021-11-18 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03393611
The ClinicalTrials.gov registry entry for NCT03393611 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 14 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 285-participant average among 173 other Myelodysplastic Syndromes trials with a reported enrollment target (95% lower). The listed sponsor is Weill Medical College of Cornell University, which has 701 total studies on file at ClinicalTrials.gov.
The record links to 4 conditions, with Myelodysplastic Syndromes appearing as the primary indexed condition, and to 5 interventions - of which Fludarabine is the first listed.
NCT03393611 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.
Frequently Asked Questions
What is clinical trial NCT03393611 about?
NCT03393611 is a clinical study titled "CPX-351 Salvage Therapy Followed by Haplo-Cord Transplant for Relapsed/Refractory Leukemia or Myelodysplastic Syndrome". This pilot study is designed to evaluate outcomes with the combination of CPX-351 salvage therapy and haplo-cord graft stem cell transplantation for subjects with relapsed or refractory AML or myelodysplastic syndrome.
What is the current status of trial NCT03393611?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 14 participants. The study started on 2012-11-30. Estimated completion is 2021-11-18.
What conditions does trial NCT03393611 study?
This clinical trial studies the following conditions: Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Myelodysplastic Syndromes, Previously Treated, Leukemia, Relapsed Adult Acute Myeloid.
What interventions are being tested in trial NCT03393611?
The interventions under investigation include: Fludarabine (DRUG), Melphalan (DRUG), CPX-351 (DRUG), Rabbit Anti-Human T-Lymphocyte Globulin (DRUG), Haplo-Cord Stem Cell Transplantation (BIOLOGICAL).
Who is sponsoring clinical trial NCT03393611?
This trial is sponsored by Weill Medical College of Cornell University, which has 701 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03393611 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Myelodysplastic Syndromes
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Phase 1 Study of Orca-Q in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies
RECRUITING · Phase 1
-
UAB 2419-CD34 Selection Using the Automated CliniMACS Prodigy
RECRUITING · Phase 1
-
A Study of TSC-100 and TSC-101 in AML, ALL and MDS in Patients Undergoing Allogeneic Peripheral Blood Stem Transplantation
RECRUITING · Phase 1
-
HM2023-05: GTB-3650 Trike for High Risk MDS and R/R AML
RECRUITING · Phase 1
-
A Study of GLB-001 in Patients With Relapsed or Refractory Acute Myeloid Leukemia or Relapsed or Refractory Higher Risk Myelodysplastic Syndromes
RECRUITING · Phase 1
-
Study of DISC-0974 (RALLY-MF) in Participants With Myelofibrosis or Myelodysplastic Syndrome and Anemia
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.